AstraZeneca's assault on GlaxoSmithKline’s position as the company selling the most-prescribed combination respiratory drug received a boost yesterday when it presented clinical data claiming ...
Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of asthma, surveyed physicians’ prescribing practices ...
AstraZeneca is developing new labelling for its combination asthma medication Symbicort that could boost its prospects against rival drug Seretide/Advair from GlaxoSmithKline, according to Datamonitor ...
Both budesonide/formoterol (Symbicort) and seretide (Advair) are combinations of inhaled steroids and long-acting beta-agonists. The question that is asked is whether one is better than the other for ...
Surveyed Physicians Who Identified Advair/Seretide/Adoair or Symbicort As the Most Efficacious Asthma Therapy Indicate High Levels of Satisfaction Across All Efficacy Attributes, According to Findings ...
The SMART (Symbicort Maintenance and Reliever Therapy) approach allows patients to increase the dose of Symbicort (a combination of an inhaled corticosteroid and long-acting bronchodilator) during ...
Subsidies for asthma inhalers will get a big shake-up from 1 August. More people will be able to have long-acting inhalers, such as Oxis and Serevent, because of relaxed prescribing rules which see ...
The FDA has issued AstraZeneca's ($AZN) least favorite form of draft guidance--the kind that helps other drugmakers develop copies of a blockbuster seller. Regulators ...
WASHINGTON, Jan. 11 (UPI) -- The anticipated approval of a new dosing regimen for AstraZeneca's Symbicort in Europe could significantly alter the asthma drug market, analysts said Wednesday. The ...
We would like to raise concerns regarding significant deficiencies in the article ‘Evidence-based asthma care', a reproduction of a review by Map of Medicine, which ...
Novartis’ Ultibro Breezhaler is more effective in patients at risk of chronic obstructive pulmonary disease (COPD) flare-ups than GlaxoSmithKline’s rival drug, Seretide, according to new data. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback